SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Claris Lifesciences shines on receiving ANDA approval for Levofloxacin Injection in US

07 Jun 2013 Evaluate

Claris Lifesciences is currently trading at Rs. 156.00, up by 1.55 points or 1.00% from its previous closing of Rs. 154.95 on the BSE.

The scrip opened at Rs. 163.45 and has touched a high and low of Rs. 163.45 and Rs. 154.65 respectively. So far 95,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 292.20 on 05-Dec-2012 and a 52 week low of Rs. 150.00 on 16-May-2013.

Last one week high and low of the scrip stood at Rs. 166.00 and Rs. 152.00 respectively. The current market cap of the company is Rs. 998 crore.

The promoters holding in the company stood at 62.06% while Institutions and Non-Institutions held 24.15% and 13.79% respectively.

Claris Lifesciences has received an Abbreviated New Drug Application (ANDA) approval for Levofloxacin Injection; having strength of 25mg/ ml in 20 ml vials in the United States of America (US). Levofloxacin Injection is an anti-infective drug administered on adults suffering from infection such as Pneumonia, Acute Bacterial Sinusitis or Complicated Urinary Tract Infection, etc. The intravenous route of administration is considered advantageous to the patient.

Claris is also one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company now has 11 ANDAs approved and has a total filing of 32 ANDAs.

Peers
Company Name CMP
Redington 281.00
Amrapali Industries 42.31
Adani Enterprises 3026.50
Rashi Peripheral 752.80
PDS 339.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: